MARKET

VKTX

VKTX

Viking Therapeutics Inc
NASDAQ
34.02
+0.22
+0.65%
Pre Market: 34.00 -0.02 -0.06% 07:05 08/13 EDT
OPEN
34.07
PREV CLOSE
33.80
HIGH
34.74
LOW
33.50
VOLUME
373
TURNOVER
--
52 WEEK HIGH
43.15
52 WEEK LOW
22.96
MARKET CAP
3.97B
P/E (TTM)
-7.2970
1D
5D
1M
3M
1Y
5Y
1D
Viking Therapeutics Price Target Cut to $65.00/Share From $75.00 by JP Morgan
Dow Jones · 1d ago
Viking Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 1d ago
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65
Benzinga · 1d ago
Viking Therapeutics price target lowered to $65 from $75 at JPMorgan
TipRanks · 2d ago
3 Best Stocks With 100%+ Upside to Buy This Week, According to Analysts
TipRanks · 2d ago
Corbus Pharmaceuticals Holdings Inc. Stock Falls 7.0%, Underperforms Peers
Dow Jones · 2d ago
Weekly Report: what happened at VKTX last week (0803-0807)?
Weekly Report · 3d ago
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
NASDAQ · 4d ago
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

Webull offers Viking Therapeutics Inc stock information, including NASDAQ: VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.